Indium In 111 pentetreotide
The original somatostatin receptor scan
Indium In 111 pentetreotide is octreotide joined to a DTPA chelator and labelled with indium-111. Approved as OctreoScan in 1994, it was the first widely used peptide-receptor imaging agent, showing neuroendocrine tumours on a gamma camera. Gallium-68 and copper-64 PET tracers have since proved more sensitive.
Manufacturer's recommended dosing (FDA label): 111 MBq (3 mCi), Single injection, Intravenous Details ↓
Recommended Dosing
Manufacturer's recommended dosing (FDA label)
From the prescribing information. Other doses studied, if any, are in the full dosing data below.
What is it?
Somatostatin receptor scintigraphy began with radiolabelled octreotide. The Rotterdam group's experience with more than 1,000 patients showed that many tumours, classically neuroendocrine ones, could be located this way, that granulomas and autoimmune processes also lit up, and that a positive scan often predicted response to octreotide treatment. They speculated that radiolabelled peptides could one day treat cancer, which is what lutetium-177 dotatate now does.
OctreoScan, approved in 1994, made the technique routine. In pulmonary carcinoid, SPECT/CT with it was more sensitive than contrast CT (96% against 87.5%); in bronchial carcinoids, 71% of patients had positive scans. Against FDG-PET in 153 patients checked against pathology, it was the better scan for well-differentiated tumours (80% against 60%) and the worse one for poorly differentiated tumours (57% against 100%), because the two tracers see different biology.
Gallium-68 and copper-64 PET tracers outperform it, and the gap is mostly about size. In 150 patients scanned with both, planar OctreoScan detected receptor-positive disease in 23%, its SPECT in 38% and gallium-68 DOTATATE PET in 72%; lesions under 2 cm were the ones it missed, while for lesions over 5 cm the scores nearly matched. Lesion by lesion against gallium-68 DOTATOC, it found 660 lesions where PET found 1,098. Copper-64 DOTATATE found twice as many lesions in a 112-patient comparison.
That matters for treatment. The NETTER-1 trial of lutetium-177 dotatate selected patients by their Krenning score on planar OctreoScan, so this older scan set the original eligibility rule; on PET, more patients and smaller lesions qualify. In one small series, the first therapy scan with lutetium-177 dotatate showed more lesions than OctreoScan had.
It has niche uses outside neuroendocrine tumours. For the small tumours that cause tumour-induced osteomalacia, pooled sensitivity was 83% on OctreoScan SPECT/CT, close to gallium-68 PET at 90% and well above FDG at 67%. Reading the scans has traps: benign uptake in the pancreatic head was seen in about one in seven patients in one series, and was more often benign than malignant.
The label advises hydration and a mild laxative to reduce radiation dose, and because octreotide can cause severe hypoglycaemia in people with insulinoma, an intravenous glucose line is recommended when insulinoma is suspected. Hypersensitivity reactions, rarely including angioedema or anaphylaxis, have been reported. Its biological half-life is about six hours, and most of it leaves through the kidneys.
Mechanism of Action
Indium-111 pentetreotide is octreotide carrying a radioactive tag, so tumours rich in somatostatin receptors show up on a gamma camera.
Somatostatin receptors
Binds somatostatin receptors on cell surfaces and concentrates in receptor-rich tumours within hours (label, clinical pharmacology).
Gamma imaging
Indium-111 emits gamma rays read by planar scintigraphy or SPECT once background activity has cleared (label).
Kidney clearance
Excreted almost entirely by the kidneys: half the dose is in the urine within 6 hours and 85% within 24 hours (label).
Published Research
Studies of indium-111 pentetreotide, from their PubMed abstracts.
The Rotterdam experience in over 1,000 patients
Scintigraphy with indium-111 DTPA-octreotide located tumours rich in somatostatin receptors and also granulomas and autoimmune processes; a positive scan often predicted a favourable response to octreotide, and the authors proposed radiolabelled peptides for therapy.
Pulmonary carcinoid
In 81 patients, SPECT/CT with indium-111 pentetreotide was positive in 50 of 55 with disease, with sensitivity of 96% against 87.5% for contrast CT and specificity of 92% against 97%.
Bronchial carcinoids
In 28 patients, 71% had OctreoScan-positive tumours, including 8 of 9 with carcinoid syndrome; the primary was positive in 13 of 16, and the scan found one primary that CT missed.
Against gallium-68 DOTATATE
A systematic review of 42 studies found gallium-68 DOTATATE more sensitive than indium-111 DTPA-octreotide in all three same-patient comparisons.
Against copper-64 DOTATATE
In 112 patients, sensitivity and accuracy were 87% and 88% for indium-111 DTPA-octreotide SPECT against 97% for copper-64 DOTATATE PET, which found twice as many lesions.
Against the therapy scan
In 10 patients scanned with indium-111 pentetreotide before lutetium-177 dotatate therapy, the scan after the first therapy dose showed more lesions (median 13.5 against 8 on SPECT/CT) and higher uptake (SUVmax 4.5 against 2.9), most of the extra lesions under a centimetre.
Uptake over time and tumour grade
In 22 patients with pancreatic or gastrointestinal neuroendocrine tumours, uptake rose between 4 and 24 hours in grade 1 tumours and fell in grade 2 (change in SUVmax +19.35 against -13.30; P < 0.05), suggesting the scan's timing may hint at grade.
Krenning scores against gallium-68 DOTATATE
In 150 patients imaged with both within a week, somatostatin-receptor disease was detected in 23% on planar OctreoScan, 38% on its SPECT and 72% on gallium-68 DOTATATE PET. For lesions under 2 cm, planar and SPECT found only 15% and 24%; for lesions over 5 cm the Krenning scores were nearly equivalent.
Lesion by lesion against gallium-68 DOTATOC
In 53 patients with metastatic neuroendocrine tumours scheduled for radionuclide therapy, gallium-68 DOTATOC PET/CT found 1,098 lesions against 660 on indium-111 pentetreotide SPECT, a lesion sensitivity of 99.9% against 60.0%.
Against FDG-PET by tumour grade
In 153 patients with gastrointestinal or pancreatic neuroendocrine tumours checked against pathology, OctreoScan was more sensitive than FDG-PET for well-differentiated tumours (80% against 60%) and less sensitive for poorly differentiated ones (57% against 100%).
Benign uptake in the pancreatic head
In 136 patients, 14.7% had benign uptake in the pancreatic head, which was 2.7 times more often benign than malignant. A pancreatic head-to-liver ratio above 1.67 separated tumour from benign uptake in this series.
Finding tumours that cause osteomalacia
Across 14 studies of 346 patients with tumour-induced osteomalacia, pooled sensitivity was 90% for gallium-68 somatostatin PET/CT, 83% for OctreoScan SPECT/CT and 67% for FDG-PET/CT; the two somatostatin methods did not differ significantly.
Dosing Data
OctreoScan is a single diagnostic intravenous injection given in a nuclear medicine department; the activity depends on whether planar or SPECT imaging is planned.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
The approved product, as its label describes it:
- Octreoscan (indium in -111 pentetreotide kit): A 10-mL vial of Indium In 111 Chloride Solution, which contains 1.1 mL or 111 MBq/mL (3 mCi/mL) Indium In 111 chloride in 0.02 N HCl at time of calibration. Forms the label lists: vials.
Source: Octreoscan (indium in -111 pentetreotide kit) label, section 16 (DailyMed version 17, effective February 21, 2022).
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Indium In 111 pentetreotide is a radioactive drug, prepared and given in nuclear-medicine departments, and its dose is an amount of radioactivity (MBq or GBq), not a weight.
This page's dosing note: “OctreoScan is dosed by radioactivity, 111 MBq for planar or 222 MBq for SPECT imaging, measured in a dose calibrator by nuclear medicine staff; no reconstitution maths applies.”
Source: this page's own note in Dosing Data below; the amount of each dose row in Dosing Data below.
Storage before and after mixing
Before mixing or first use: “The Octreoscan kit should be stored refrigerated at 2° to 8°C (36° to 46°F).”
After mixing or first use: “After reconstitution, store at controlled room temperature 20° to 25°C (68° to 77°F).”
Source: Octreoscan (indium in -111 pentetreotide kit) label, sections 16 and 2 (DailyMed version 17, effective February 21, 2022).
How it is taken
As the approved label gives it: Intravenous (Single injection; Label: planar imaging).
Source: Manufacturer's recommended dosing (FDA label): the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: a half-life of biological half-life about 6 hours. After about five half-lives almost none is left.
How long the doses were given: Label: planar imaging: One scan series; Label: SPECT imaging: One scan series.
When effects appear: unknown; no source on this page gives a time to effect for Indium In 111 pentetreotide. Results reported in the studies are under Published Research.
Source: half-life: OctreoScan prescribing information (DailyMed set 93d8f3b2, effective February 21, 2022); Manufacturer's recommended dosing (FDA label), the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Hypersensitivity reactions, rarely angioedema or anaphylaxis; Risk of hypoglycaemia in people with insulinoma. Full list and cautions ↓
When to stop or get help: unknown; the label's warnings summary we read gives no rule for stopping Indium In 111 pentetreotide. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the label and studies above”).
Interactions
- octreotide (therapeutic doses): may reduce scan sensitivity; consider temporarily suspending octreotide before the scan and monitor for withdrawal
Every peptide's record, with its source: the interaction matrix.
Source: Curium. OCTREOSCAN (kit for indium In 111 pentetreotide) US prescribing information, precautions. DailyMed version of February 21, 2022, read October 3, 2026.
Checking what you bought
Unknown: no published independent test of Indium In 111 pentetreotide products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: FDA Approved (Approved in the US as OctreoScan (kit for preparation of indium In 111 pentetreotide), NDA 020314, on June 2, 1994 (Drugs@FDA via openFDA and the OctreoScan label effective February 21, 2022, read October 3, 2026)). Sport: Not on the 2026 List.
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the label and studies above.
Contraindications & Cautions
Precautions from the OctreoScan label (DailyMed, effective February 21, 2022).
Legal Status
Indium In 111 pentetreotide is an approved prescription diagnostic in the US.
Frequently Asked Questions
?What is an OctreoScan?
A gamma-camera scan after an injection of indium-111-labelled octreotide, which binds somatostatin receptors on neuroendocrine tumours.
?Is OctreoScan still used?
It is still approved, but gallium-68 and copper-64 DOTATATE PET scans are more sensitive in head-to-head comparisons and have largely replaced it where available.
?Why is a glucose drip sometimes needed?
Octreotide can cause severe low blood sugar in people with insulinomas, so the label recommends an intravenous glucose line when insulinoma is suspected.
?Why is OctreoScan used less now?
Gallium-68 and copper-64 somatostatin PET tracers detect more disease, especially lesions under 2 cm: in one 150-patient comparison, 72% against 23% on planar OctreoScan.
?Can OctreoScan still decide eligibility for lutetium-177 dotatate?
It set the original rule: the NETTER-1 trial used the Krenning score on planar OctreoScan. Where PET is available it is now generally preferred, and it qualifies more patients.
?How much radiation is injected?
The label recommends 111 MBq (3 mCi) for planar imaging and 222 MBq (6 mCi) for SPECT, with hydration and a mild laxative to lower the dose absorbed.
References
- [fda] US FDA, Drugs@FDA (openFDA): OCTREOSCAN, NDA 020314 (June 2, 1994). Read October 3, 2026.
- [fda-pi] FDA. OctreoScan (kit for indium In 111 pentetreotide) US prescribing information (DailyMed set 93d8f3b2-1216-41dc-a63d-0e812b33891d, version 17, effective February 21, 2022). Read October 3, 2026.
- [pubmed] Krenning EP, et al. "Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients." Eur J Nucl Med, 1993;20(8):716-31. PMID: 8404961.
- [pubmed] Chiaravalloti A, et al. "111In-Pentetreotide SPECT/CT in Pulmonary Carcinoid." Anticancer Res, 2015;35(7):4265-70. PMID: 26124388.
- [pubmed] Granberg D, et al. "Octreoscan in patients with bronchial carcinoid tumours." Clin Endocrinol (Oxf), 2003;59(6):793-9. PMID: 14974924.
- [pubmed] Deppen SA, et al. "68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis." J Nucl Med, 2016;57(6):872-8. PMID: 26769864.
- [pubmed] Pfeifer A, et al. "64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients." J Nucl Med, 2015;56(6):847-54. PMID: 25952736.
- [pubmed] Hotta M, et al. "Pre-treatment (111)In-pentetreotide SPECT/CT vs. baseline (177)Lu-DOTATATE SPECT/CT: are there differences in lesion uptake and detectability?." Ann Nucl Med, 2025;39(7):747-753. PMID: 40227560.
- [pubmed] Ohba M, et al. "Quantification of (111)In-Pentetreotide Single Photon Emission Computed Tomography Images in Gastrointestinal Neuroendocrine Tumors and Possibility of Grade Prediction." Nucl Med Mol Imaging, 2025;59(3):194-200. PMID: 40385366.
- [clinical-trial] Hope TA, et al. "(111)In-Pentetreotide Scintigraphy Versus (68)Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden." J Nucl Med, 2019;60(9):1266-1269. PMID: 30850506.
- [clinical-trial] Van Binnebeek S, et al. "Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours." Eur Radiol, 2016;26(3):900-9. PMID: 26162577.
- [clinical-trial] Squires MH 3rd, et al. "Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach." Ann Surg Oncol, 2015;22(7):2295-301. PMID: 25786743.
- [pubmed] Jiang Y, et al. "Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis." Nucl Med Commun, 2020;41(4):370-376. PMID: 32000173.
- [clinical-trial] Derakhshan JJ, et al. "Prevalence and quantitative analysis of indium-111 pentetreotide (Octreoscan) uptake in the pancreatic head on SPECT/CT imaging: establishing a region of interest-based pathological uptake threshold." Nucl Med Commun, 2019;40(7):727-733. PMID: 31033780.
- [fda-pi] OctreoScan (kit for the preparation of indium In-111 pentetreotide) US prescribing information (Curium; DailyMed set 93d8f3b2, version 17, effective February 21, 2022), Dosage and Administration and Clinical Pharmacology; read October 6, 2026.
Sources & Citations
Studies were read from their PubMed abstracts; the label from DailyMed (set 93d8f3b2, effective February 21, 2022), read October 6, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.